Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Chronic Low Back Pain
Phase NA
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This two-arm randomized controlled trial aims to test the preliminary effect of home-based mindfulness-based meditation and transcutaneous auricular vagus nerve stimulation on managing pain and depressive symptoms among community-dwelling older adults with chronic low back pain and depressive symptoms; and the effect of home-based mindfulness-based meditation and transcutaneous auricular vagus nerve stimulation on the host Brain-Gut Axis.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: MBM — MBM is designed to be applied for 20 minutes per session daily, five days per week, for 8 weeks.
  • Device: VNSM — The VNSM consists of a single daily session, five days per week, comprising 20 minutes of taVNS immediately followed by 20 minutes of MBM (total ≈ 40 minutes) for 8 weeks.

Primary Outcomes

  • Change in pain intensity and interference (Baseline and 2 weeks and 8 weeks)
  • Change in depressive symptoms (Baseline and 2 weeks and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-30
Completion: 2027-12-31
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Florida State University
Contact Information
Study Contact:
Jie Chen
18506450657
jc22db@fsu.edu
Jie Chen
8506450657
jc22db@fsu.edu
Florida State University
Interventions
  • Behavioral: MBM — MBM is designed to be applied for 20 minutes per session daily, five days per week, for 8 weeks.
  • Device: VNSM — The VNSM consists of a single daily session, five days per week, comprising 20 minutes of taVNS immediately followed by 20 minutes of MBM (total ≈ 40 minutes) for 8 weeks.
Study Locations (1 sites)
Florida State University, Tallahassee, Florida 32306 United States
Eligibility Criteria
Inclusion Criteria: 1. aged 50 to 85 years old 2. intact cognition (examined by the Mini-Mental State Exam, ≥ 24) 3. experiencing moderate low back pain daily or almost every day at least the previous three months (≥3 out of 10 on numeric rating scale \[NRS\]) 4. experiencing elevated depressive symptoms with the patient health questionnaire (PHQ-9) total score ranging between 5 to 19 5. able to speak and read English 6. not intent to change medication regimens for pain throughout the trial. Exclusion Criteria: 1. serious underlying illness (e.g., malignant neoplasms), 2. other psychosis, 3. elevated suicide risk as indicated by the Columbia-Suicide Severity Rating Scale (C-SSRS) score \> 2, 4. function limitation precluded the meditation practice, 5. participated meditation program before, 6. any other conditions/contraindications that prohibit the application of taVNS including but not limited to any current or past history of cardiovascular disorders, recent ear trauma, and metal implants above the level of the neck, 7. no access to the internet.
Conditions PICS, Anxiety, Depression - Major Depres...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Survivors of critical illness are at high risk for mental health issues such as anxiety, depression, and PTSD. This single-site, randomized controlled trial at the Medical University of South Carolina will enroll 150 patients to compare outcomes between a behavioral health Collaborative Care Model (BH CoCM) and usual care (attention control). The intervention includes digital tools (Neuroflow), behavioral health coaching, and psychiatric support.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioral Health Collaborative Care Model — behavioral health collaborative care model in ICU recovery patients and families

Primary Outcomes

  • Depression (Enrollment to 6 months)
  • Anxiety (enrollment to six months)
  • Post-Traumatic Stress (enrollment to six months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-30
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: Health Resources and Services Administration (HRSA)
Principal Investigators:
  • Rita Bakhru, MD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Rita Bakhru, MD
8437924148
bakhru@musc.edu
Dr. Bakhru
8437924148
bakhru@musc.edu
Medical University of South Carolina
Interventions
  • Behavioral: Behavioral Health Collaborative Care Model — behavioral health collaborative care model in ICU recovery patients and families
Study Locations (1 sites)
Medical University of South Carolina, Charleston, South Carolina 29407 United States
Eligibility Criteria
Inclusion Criteria: \- Attendance at the MUSC ICU Recovery Clinic within 180 days of discharge from the hospital Exclusion Criteria: * ICU Admission was due to a primary addiction diagnosis (eg alcohol withdrawal or delirium tremens requiring ICU care) * Serious Mental Illness such as Schizophrenia, psychotic disorder, acute mania * Late Stage Dementia or Cognitive Impairment * Limited English or Spanish Proficiency * Lack of regular access to a computer, tablet or mobile device with internet access
Conditions Major Depressive Disorder (MDD)
Phase PHASE4
Enrollment 14
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Nicotine transdermal patch — The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).
  • Drug: PET Scan with [18F] VAT — All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.

Primary Outcomes

  • Change in Hamilton Depression Rating Scale-17 (HAMD) score. (Before and after 8 days of treatment with nicotine.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-10-03
Completion: 2029-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 14 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stony Brook University
Collaborators: National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Principal Investigators:
  • Ramin Parsey, MD, PhD (PRINCIPAL_INVESTIGATOR) - Stony Brook University
Contact Information
Study Contact:
Julianna Lizzul
631-638-0291
julianna.lizzul@stonybrookmedicine.edu
Julianna Lizzul
631-638-0291
julianna.lizzul@stonybrookmedicine.edu
Stony Brook University: Dept of Psychiatry
Ramin Parsey, M.D., Ph.D.
Stony Brook University: Dept of Psychiatry
Interventions
  • Drug: Nicotine transdermal patch — The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).
  • Drug: PET Scan with [18F] VAT — All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.
Study Locations (1 sites)
Stony Brook University: Dept of Psychiatry, Stony Brook, New York 11794 United States
Eligibility Criteria
Inclusion Criteria: For Non-Depressed Participants: * Age range 18 to 65 years old. * Capacity to consent (able to read, understand, and sign informed consent). For Participants with MDD * Age range 18 to 65 years old. * Capacity to consent (able to read, understand, and sign informed consent). * Major Depressive Disorder (MDD) as primary diagnosis and currently in a major depressive episode * Score of at least 29 on the Montgomery-Asberg Depression Rating Scale (MADRS). Exclusion Criteria: For Non-Depressed Participants: * Nicotine use, including tobacco, e-cigarettes, nicotine patch, nicotine gum, within the past year \[except for occasional users, who cannot use nicotine products in the week before the scan\]. * Need for use of medication during the study that will affect cholinergic levels. * Problematic drug/alcohol use that is judged sufficient to interfere with study procedures during the treatment period or impact participant safety. * Significant active physical illness or neurological deficit that may affect brain function or imaging. * Significant eye conditions such as keratoconus and/or need for rigid contact lenses. * Current or lifetime history of a major psychiatric diagnosis. * Any MRI contraindications, including recent tattoos, metal implants, pacemaker, metal prostheses, orthodontic appliances, or presence of shrapnel that are contraindicated for MRI. * Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is pregnant, currently breastfeeding, or planning to conceive during the course of study participation. * Blood donation within 8 weeks of the \[18F\]VAT scan. For Participants with MDD * Nicotine use, including tobacco, e-cigarettes, nicotine patch, nicotine gum, within the past year \[except for occasional users, who cannot use nicotine products in the week before the scan\]. * Currently on effective antidepressant medications or need for use of medications that target the cholinergic system. * Problematic drug/alcohol use that is judged sufficient to interfere with study procedures during the treatment period or impact participant safety. * Significant active physical illness or neurological deficit that may affect the brain function or imaging. * Significant eye conditions such as keratoconus and/or need for rigid contact lenses. * Current or lifetime major psychiatric diagnosis other than MDD. * Life-time history of psychosis or current psychosis. * Significant risk for suicide. * Any MRI contraindications, including recent tattoos, metal implants, pacemaker, metal prostheses, orthodontic appliances, or presence of shrapnel that are contraindicated for MRI. * Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is pregnant, currently breastfeeding, or planning to conceive during the course of study participation. * Blood donation within 8 weeks of the \[18F\]VAT scan.
Conditions Depression - Major Depressive Disorder, ...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Schizophrenia (SCH), major depressive disorder (MDD), and bipolar disorder (BPD) are prevalent, disabling psychiatric conditions that not only cause significant suffering for affected individuals and their families but also impose a substantial socioeconomic burden and challenge societal well-being. Addressing the mental health challenges faced by patients, their families, and the healthcare system is a critical global public health priority. However, a comprehensive and systematic precision treatment approach for mental disorders remains largely absent in current clinical practice. This study leveraged pharmacogenomic insights tailored specifically to the Chinese Han population to guide individualized medication selection. The approach incorporated quantitative assessment-based treatment protocols alongside therapeutic drug monitoring throughout the treatment process. The overarching goal was to establish a systematic precision treatment model that integrates "quantitative assessment-based treatment + pharmacogenomics + therapeutic drug monitoring." This model aims to optimize treatment outcomes, enhance safety, improve efficiency, and reduce costs, ultimately benefiting patients with psychiatric disorders.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: Multigenetic Pharmacogenomics-Guided Treatment (MPGT) — In the guidance group, drug types and dosages were adjusted based on the results of Pharmacogenetic TESTING.

Primary Outcomes

  • Change from baseline in Positive and Negative Syndrome Scale (PANSS) (Weeks 4, 8, and 12 of the treatment duration)
  • Change from baseline in Hamilton Depression Rating Scale (HAMD) (Weeks 4, 8, and 12 of the treatment duration)
  • Change from baseline in Young Mania Rating Scale (YMRS) (Weeks 4, 8, and 12 of the treatment duration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-11
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Contact Information
Study Contact:
Weihua Yue
86-010-82805307
dryue@bjmu.edu.cn
Weihua Yue
010-82805307
dryue@bjmu.edu.cn
Peking University Sixth Hostipal
Interventions
  • Other: Multigenetic Pharmacogenomics-Guided Treatment (MPGT) — In the guidance group, drug types and dosages were adjusted based on the results of Pharmacogenetic TESTING.
Study Locations (1 sites)
Peking University Sixth Hostipal, Beijing, Beijing Municipality 100191 China
Eligibility Criteria
Inclusion Criteria: * Schizophrenia: (1) Age 18-65 years, no gender restriction, Han ethnicity; (2) Diagnosis confirmed using the MINI-International Neuropsychiatric Interview (MINI) tool, meeting the DSM-5 criteria for schizophrenia; (3) Baseline Positive and Negative Syndrome Scale (PANSS) score ≥ 60; (4) Education level of middle school or higher, no language barriers, able to cooperate with assessment and treatment, and informed consent obtained from the patient or guardian. * Depressive Disorder: (1) Age 18-65 years, no gender restriction, Han ethnicity; (2) Diagnosis confirmed using the MINI tool, meeting the DSM-5 criteria for depressive disorder; (3) Baseline Hamilton Depression Rating Scale (HAMD-17) score ≥ 17; (4) Education level of middle school or higher, no language barriers, able to cooperate with assessment and treatment, and informed consent obtained from the patient or guardian. * Bipolar Disorder: (1) Age 18-65 years, no gender restriction, Han ethnicity; (2) Diagnosis confirmed using the MINI tool, meeting the DSM-5 criteria for manic or hypomanic episodes in bipolar disorder; (3) Baseline Young Mania Rating Scale (YMRS) score ≥ 13; (4) Education level of middle school or higher, no language barriers, able to cooperate with assessment and treatment, and informed consent obtained from the patient or guardian. Exclusion Criteria: * Patients with a history of or currently meeting the DSM-5 criteria for the following diagnoses: organic mental disorders, schizoaffective disorder, intellectual disability, dementia, other cognitive disorders, alcohol or drug dependence, and Axis II disorders including personality disorders; * Patients with severe suicidal tendencies (as assessed by the MINI Chinese version suicide module with a moderate risk or higher), or those at risk of harming others; * Patients with severe or unstable physical illnesses; * Narrow-angle glaucoma; * A history of epilepsy or seizures; * Known pregnancy and/or breastfeeding, or those planning to become pregnant; * Participation in another clinical trial, or unwilling or unable to complete the full course of this trial; * Participants deemed unsuitable by the investigator.
Conditions Insomnia
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial (RCT) study aims to evaluate the effectiveness of a digital-based multimodal sleep management program compared to a waitlist control group in improving sleep-related outcomes, including insomnia severity, daytime sleepiness, objective sleep parameters, and sleep reactivity to stress, as well as psychological health indices, such as depression, anxiety, and resilience. Additionally, this study seeks to examine the mediating role of different chronotypes in the effectiveness of the sleep intervention on the outcomes of interest.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: Waitlist control group — The participants in the waitlist control group will be informed that they are on a waiting list during the intervention period, serving as a no-treatment control. They will receive the sleep intervention (i.e., the digital-based sleep management program) four weeks after the intervention period is completed.
  • Behavioral: digital-based multimodal sleep management program — The digital-based multimodal sleep management program consists of (1) sleep hygiene education, (2) sleep restriction, and (3) mindfulness breathing exercises. The program is internet-integrated and delivered via Google Meet, with 45-minute weekly sessions over four weeks. To increase participants' adherence to the sleep management program , the course instructor will request the participants to record their daily sleep diaries (time to bed, time to sleep, wake time during sleep and wake time) and sleep journals(practices of sleep hygiene, sleep restriction and mindfulness breathing exercise) in the mobile app for at least five consecutive days each week.

Primary Outcomes

  • Insomnia Severity:The Insomnia Severity Index (ISI) (T0 = baseline; T1 = immediately after intervention; T2 = 4 weeks after intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-24
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taipei Medical University
Collaborators: National Science and Technology Council, Taiwan
Contact Information
Study Contact:
Pei-Shan Tsai, PhD
+886227361661
ptsai@tmu.edu.tw
Pei-Shan Tsai, PhD
+886227361661
ptsai@tmu.edu.tw
Taipei Medicine University
Interventions
  • Other: Waitlist control group — The participants in the waitlist control group will be informed that they are on a waiting list during the intervention period, serving as a no-treatment control. They will receive the sleep intervention (i.e., the digital-based sleep management program) four weeks after the intervention period is completed.
  • Behavioral: digital-based multimodal sleep management program — The digital-based multimodal sleep management program consists of (1) sleep hygiene education, (2) sleep restriction, and (3) mindfulness breathing exercises. The program is internet-integrated and delivered via Google Meet, with 45-minute weekly sessions over four weeks. To increase participants' adherence to the sleep management program , the course instructor will request the participants to record their daily sleep diaries (time to bed, time to sleep, wake time during sleep and wake time) and sleep journals(practices of sleep hygiene, sleep restriction and mindfulness breathing exercise) in the mobile app for at least five consecutive days each week.
Study Locations (1 sites)
Taipei Medicine University, Taipei, 11031 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Registered as a full-time student 2. Aged 18 to 26 years old 3. Experiencing insomnia for at least three months 4. Currently own and use a personal mobile device 5. Ability to read and speak Chinese 6. Not taking hypnotics, sedatives, or antidepressants 7. Not pregnant or lactating Exclusion Criteria: 1. Using a smartphone model that cannot support the app 2. Currently using other sleep program apps 3. Meeting a STOP-BANG score of ≥3
Conditions Psychiatric Disorder
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Genetic analyses conducted on patient with psychiatric disorders assessed at the expert centres resulted in the identific action of genetic variants associated with psychiatric disorders (Courtois, 2020). These data require further genetic and functional analyses. The first objective of this study is to investigate the disease-related inheritance of genetic variants in the families of individuals in whom these variants have been identified. The second objective is to explore the functional consequences of disease-associated genetic variants in patients cells and those of their relatives with and without these variants. The present project aims to enrich existing biocollections with DNA from blood or saliva from relatives of patients identified with genetic variants. In addition, we wish to collect hair follicules from patients with identified genetic variants of interest and their family members who wish to participate in the study. These hair samples with SNA will be used to dedifferentiate the isolated cells into induced pluripotent stem cells (IPSCs), and then to differentiate them into cells expressing the gene of interest, such as neurons or astrocytes, or into more complex systems, such as brain organoids.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Genetic: study of the transmission of genetic variants — the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA

Primary Outcomes

  • Measure of the probability of having a psychiatric disorder given the presence of the genetic variant studied. (through study completion, an average of 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-15
Completion: 2028-09-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondation FondaMental
Principal Investigators:
  • Marion Leboyer, MD PhD (STUDY_CHAIR) - Fondation FondaMental
  • Stephane JAMAIN, PhD (STUDY_DIRECTOR) - Institut National de la Santé Et de la Recherche Médicale, France
Contact Information
Study Contact:
Stephane JAMAIN, PhD
149813775
stephane.jamain@inserm.fr
Agnes PELLETIER, MD, PhD
01.49.81.30.51
agnes.pelletier@aphp.fr
Hopital Albert Chenevier
Interventions
  • Genetic: study of the transmission of genetic variants — the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA
Study Locations (1 sites)
Hopital Albert Chenevier, Créteil, 94000 France
Eligibility Criteria
Inclusion Criteria: * For patients: * Subjects suffering from (according to DSM IV criteria) : Bipolar disorder, Unipolar depression, Schizophrenia, Autism spectrum disorder * Age over 18 years * Subject affiliated to the social security system * Including patients under guardianship, curatorship, * Patients included in the Fondation FondaMental cohort whose genetic analyses have revealed the need for comparative and functional genetic studies. * Having signed the consent form For relatives : * Age over 18 years * Relative of patient included in the Fondattion FondaMental cohort * Including relative under guardianship, curatorship * Having signed the consent * Affiliated to social security Exclusion Criteria: * For all subjects: * Any condition that, in the opinion of the investigator, would make the subject's participation in the study undesirable or that would compromise compliance with the protocol * Persons deprived of liberty * Inability to understand French
Conditions Sexuality, Depression, Pregnancy Related
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This experimental, randomized controlled, single-blind study includes intervention and control groups. Pregnant women between 16 and 20 weeks of gestation who meet the inclusion criteria and agree to participate will be included in the study. Pregnant women will be randomly assigned to groups. Pre-test data will be collected from both groups. The intervention group will receive sexual counseling training in two sessions, face-to-face and in groups, until week 22. Second test data will be collected after week 37 (before delivery), and final test data will be collected three months after delivery. This study is expected to have a significant impact on women's lives, as this topic is considered taboo in our country, leading to a lack of open discussion and the prevalence of misconceptions and false beliefs (sexual myths).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Other: sexuality health education group — This study will provide sexual counseling to pregnant women. Results will be collected both before delivery and at 3 months postpartum. The difference is that it covers both the pregnancy and postpartum periods.

Primary Outcomes

  • Female Sexual Function Scale (20.pregnancy week until postpartum third month)
  • Depression Anxiety Stress-21 Scale (22. pregnancy week until postpartum third month)
  • Sexual Life Quality Scale - Women (22.pregnancy week - postpartum third month)
  • Marital Adjustment Scale (22. pregnancy week until postpartum third month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-15
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ordu University
Principal Investigators:
  • Gizem YILDIZ, MSc (STUDY_DIRECTOR) - Ordu University
Contact Information
Study Contact:
Gizem YILDIZ, MSc
+905442390166
gizemg.2795@gmail.com
Gizem YILDIZ, MSc
05442390166
gizemg.2795@gmail.com
Gizem YILDIZ, MSc.
05442390166
gizemg.2795@gmail.com
Ordu University
Interventions
  • Other: sexuality health education group — This study will provide sexual counseling to pregnant women. Results will be collected both before delivery and at 3 months postpartum. The difference is that it covers both the pregnancy and postpartum periods.
Study Locations (1 sites)
Ordu University, Altinordu, Ordu 52200 Turkey (Türkiye)
Eligibility Criteria
Eligibility criteria; * Volunteers to participate in the research, * primary school graduate, * Pregnant between 16-20 weeks * Having a single pregnancy, * Able to understand and speak Turkish, * Living with his wife for the past four weeks, * No threat of abortion or premature birth, Exclusion Criteria: * Someone who has been diagnosed with a chronic illness, * People with diagnosed physical and mental health issues, * Someone who has been diagnosed with a psychological disorder, * Having a high-risk pregnancy, * Having an IVF pregnancy, * Low threat, * Anyone who has been diagnosed with any sexually transmitted disease, either themselves or in their partner, * Those using medications that may negatively affect sexual function, * including antipsychotics, antihypertensives, phenobarbital, and opioids.
Conditions Burnout, Professional, Stress, Psycholog...
Phase NA
Enrollment 180
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, randomized, controlled clinical trial in which clinicians from University of Pennsylvania Health Systems (UPHS) including Penn Medicine- Lancaster General Health (LGH) and Massachusetts General Hospital (MGH) are offered a well-known program to help reduce clinician burnout: Sudarshan Kriya Yoga (SKY) Breathing and Sahaj Meditation Intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Sudarshan Kriya Yoga (SKY) Breathing and Sahaj Meditation — The SKY intervention is comprised of a week of baseline HRV and sleep metric readings, followed by an onboarding week of 3-day, 3.5 hours/day, online SKY workshops with a live instructor (10.5 hours total), followed by weekly online follow-up sessions with a live instructor (1 hour each) for a period of 4 weeks. Clinicians also practice on their own daily for 45 minutes during these 4 weeks and wear an Oura Ring continuously. They do not have to do their daily practice on the days that they have a follow-up session. Well-being and burnout metrics will be assessed using PFI Week 1, Week 4, and Week 6. Evaluation of the impact of the program on other factors as measured by other questionnaires Week 1 and Week 6. HRV and sleep metrics will be used as a physiologic marker of well-being and will be measured continuously via Oura Ring.
  • Other: Health Education Program (HEP) — The HEP coaches will provide these sessions online with an initial onboarding week of 2-day, 3 hours/day online HEP workshop followed by weekly online follow up sessions for 2 hours each with a live instructor. They will also pursue 45 min of daily practice for a period of 4 weeks. They do not have to do their daily practice on the days that they have a follow-up session. Well-being and burnout metrics will be assessed using PFI Week 1, Week 4, and Week 6. Evaluation of the impact of the program on other factors as measured by other questionnaires Week 1 and Week 6. HRV and sleep metrics will be used as a physiologic marker of well-being and will be measured continuously via Oura Ring.

Primary Outcomes

  • Evaluation of the effect of well-being foundational programs on burnout in clinicians at hospital health systems utilizing the Stanford Professional Fulfilment Index. (Assess at Baseline (week1), Midpoint (week 4), and Endpoint (week 6).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-15
Completion: 2026-05
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lancaster General Hospital
Collaborators: Massachusetts General Hospital
Principal Investigators:
  • Mrinalini Meesala, MD (PRINCIPAL_INVESTIGATOR) - Penn Medicine / Lancaster General Hospital
Contact Information
Study Contact:
Halle Becker, MPH
7175441777
Halle.Becker@pennmedicine.upenn.edu
Jonathan Derr, MBA
7175441777
Jonathan.Derr@pennmedicine.upenn.edu
Jagpreet Chhatwal, PhD
617-724-4487
JagChhatwal@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Behavioral: Sudarshan Kriya Yoga (SKY) Breathing and Sahaj Meditation — The SKY intervention is comprised of a week of baseline HRV and sleep metric readings, followed by an onboarding week of 3-day, 3.5 hours/day, online SKY workshops with a live instructor (10.5 hours total), followed by weekly online follow-up sessions with a live instructor (1 hour each) for a period of 4 weeks. Clinicians also practice on their own daily for 45 minutes during these 4 weeks and wear an Oura Ring continuously. They do not have to do their daily practice on the days that they have a follow-up session. Well-being and burnout metrics will be assessed using PFI Week 1, Week 4, and Week 6. Evaluation of the impact of the program on other factors as measured by other questionnaires Week 1 and Week 6. HRV and sleep metrics will be used as a physiologic marker of well-being and will be measured continuously via Oura Ring.
  • Other: Health Education Program (HEP) — The HEP coaches will provide these sessions online with an initial onboarding week of 2-day, 3 hours/day online HEP workshop followed by weekly online follow up sessions for 2 hours each with a live instructor. They will also pursue 45 min of daily practice for a period of 4 weeks. They do not have to do their daily practice on the days that they have a follow-up session. Well-being and burnout metrics will be assessed using PFI Week 1, Week 4, and Week 6. Evaluation of the impact of the program on other factors as measured by other questionnaires Week 1 and Week 6. HRV and sleep metrics will be used as a physiologic marker of well-being and will be measured continuously via Oura Ring.
Study Locations (6 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Princeton Medical Center / Princeton Health affiliated sites, Plainsboro, New Jersey 08536 United States
Penn Medicine Lancaster General Health, Lancaster, Pennsylvania 17602 United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania 19104 United States
Pennsylvania Hospital, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: * 25-70 years of age, * UPHS or MGH clinician (physician, APP, CRNP, PA, psychologist), * Access to smart phone and internet, * Ability to give informed consent, * Interested in wearing an Oura ring and being part of a study to evaluate breath and meditation-derived exercises, * Willing to do relaxation exercise every day for 4 weeks. Exclusion Criteria: * Currently maintaining a regular/daily mind-body program practice (eg. meditation, yoga or breathing techniques), * Atrial fibrillation, * Pacemaker/defibrillator, * Untreated or severe obstructive sleep apnea (AHI\>=30), * History of diaphragm paralysis, * Unable or unwilling to complete the workshop, * Severe chronic obstructive pulmonary disease (COPD), * Severe valvular heart disease, * Prior or planned chest/abdominal or nasal/facial surgery within 6 months, * Severe psychiatric illness (e.g. schizophrenia, schizoaffective disorder, bipolar disorder), active substance use, seizure disorder or major somatic illness (uncontrolled hypertension, lung disease, liver disease, cancer or heart disease).
Conditions Depression, Functional Impairment
Phase NA
Enrollment 5370
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Mental illnesses often go undiagnosed or untreated in low-income settings. Mental health care may be especially important for the elderly - events in the lives of the elderly, like illnesses or deaths of peers, may put these individuals at high risk of mental illness. The study will constitute a randomized controlled trial aimed at reducing depression among elderly women. Through two interventions, the investigators will aim to improve women elder's outlook on life and relationships through cognitive behavioral therapy (CBT) and facilitated group activities. There will be a total of four treatment arms: one for CBT during home visits, one for facilitated group activities, one for both, and a control group receiving neither the CBT nor facilitated group activities. All activities will be delivered by lay government community volunteers. Randomization for group activities will be at the village level, and randomization for CBT will be at the individual-level within each village. Investigators will track outcomes of the elderly at two points in time: immediately after the main 12-week intervention period and 6 months after the main intervention period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: CBT — Cognitive behavioral therapy delivered by community resource persons via home visits.
  • Behavioral: Group Activities — Weekly hour-long group activities delivered by community resource persons in community spaces.

Primary Outcomes

  • Depression Score (Assessed at 0 months after the intervention)
  • Depression Score (Assessed at 6 months after the intervention)
  • Difficulty in performing daily activities/Functional impairment score (Assessed at 0 months after the intervention)
  • Difficulty in performing daily activities/Functional impairment score (Assessed at 6 months after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-20
Completion: 2028-12
Eligibility
Age: 55 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 5370 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Bureau of Economic Research, Inc.
Collaborators: Abdul Latif Jameel Poverty Action Lab
Contact Information
Study Contact:
Esther Duflo, PhD
(617) 324-4867
eduflo@mit.edu
Shrddha Rajesh (Senior Research Associate at J-PAL)
+91 96770 25388
srajesh@povertyactionlab.org
JPAL SA at IFMR
Interventions
  • Behavioral: CBT — Cognitive behavioral therapy delivered by community resource persons via home visits.
  • Behavioral: Group Activities — Weekly hour-long group activities delivered by community resource persons in community spaces.
Study Locations (2 sites)
JPAL SA at IFMR, Chennai, Tamil Nadu 600018 India
JPAL SA at IFMR, Chennai, Tamil Nadu India
Eligibility Criteria
Inclusion Criteria: * At least 55 years of age * Women Exclusion Criteria: * Those with hearing, speech or mental impairment
Conditions Depression
Phase PHASE2
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The investigators hypothesize that brief behavioral therapy and targeted propofol infusion in depressed geriatric patients will augment subsequent slow wave sleep and improve clinical and cognitive outcomes. The team will recruit 70 participants for a double-blinded placebo controlled randomized controlled trial. Two propofol infusions, 2-6 days apart, will be administered, targeting either a low propofol dose arm (minimal EEG slow waves, brain effect-site concentration 1-2 mcg/ml) or moderate dose propofol arm (maximal induction of EEG slow waves, brain effect site concentration of \>2.5 mcg/ml). The pharmacologic intervention will be paired with 3-4 sessions of Brief Behavioral Therapy for Insomnia for all participants. To minimize bias, there will be no specific gender or ethnic background consideration for enrollment. This will be a single site investigation at Washington University Medical Center.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: Propofol — Targeted propofol infusion in TRD patients will induce sedation. Dosage of propofol is determined based upon EEG markers and treatment arm.
  • Diagnostic Test: Electroencephalography (EEG) — EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
  • Behavioral: Brief Behavioral Therapy for Insomnia — Trained staff will provide evaluation and up to 3 follow up appointments of BBTI for all participants. These will be done remotely to assess behavioral approaches to improve overall sleep habits.

Primary Outcomes

  • Change in SWS duration (Pre-infusion and on the nights of propofol infusions)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-04
Completion: 2028-05-01
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Ben Palanca, MD PhD (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Sarah E Knarr
314-362-2415
knarr.sarah@wustl.edu
Sarah E Knarr
314-362-2415
knarr.sarah@wustl.edu
Washington University School of Medicine/Barnes-Jewish Hospital
Ben Palanca, MD PhD
Washington University School of Medicine/Barnes-Jewish Hospital
Interventions
  • Drug: Propofol — Targeted propofol infusion in TRD patients will induce sedation. Dosage of propofol is determined based upon EEG markers and treatment arm.
  • Diagnostic Test: Electroencephalography (EEG) — EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
  • Behavioral: Brief Behavioral Therapy for Insomnia — Trained staff will provide evaluation and up to 3 follow up appointments of BBTI for all participants. These will be done remotely to assess behavioral approaches to improve overall sleep habits.
Study Locations (1 sites)
Washington University School of Medicine/Barnes-Jewish Hospital, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Age 60 or greater * English speaking (as an interpreter will not be readily available should a participant need to convey any safety concerns during the propofol infusion sessions or require guidance on conducting at-home sleep recordings) * Depression (non-responsive to at least one adequate trial of oral antidepressants for current episode). Exclusion Criteria: * Presence of symptomatic coronary artery disease * Presence of marked congestive heart failure/cardiomyopathy(NYHA \> Class III, LVEF \<40%, greater than mild RV systolic dysfunction) * Prior reaction to propofol * Resting heart rate \< 50 bpm * Treatment with Electroconvulsive therapy/Transcranial Magnetic Stimulation/vagal nerve stimulation within 6 weeks * Body mass index \> 35 * C-SSRS of 4 or greater (active suicidal ideation with some intent and with/without a specific plan) * MoCA score \< 23 (at least mild dementia) * Schizophrenia * Bipolar disorder * Non-prescribed use of amphetamines, opioids, cocaine, or phencyclidine; Urine THC \> 150 ng/ml * Intake of \> 14 beers/week (or equivalent) * Anesthetic exposure in the past 4 weeks * Concurrent use of benzodiazepines \> 2 mg/day lorazepam or equivalent, trazodone \> 50 mg/day, or gabapentin \> 600mg/day.
Conditions Depression
Phase PHASE2
Enrollment 141
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Psilocybin — The psilocybin used in this study is synthesized under Good Manufacturing Practice (GMP) guidelines and is provided in a capsule containing 25 mg of synthetic psilocybin.
  • Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) — Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear.
  • Device: Sham taVNS — Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear. In the sham condition, the device will simulate the sensations of active taVNS without delivering therapeutic stimulation.

Primary Outcomes

  • Montgomery-Åsberg Depression Rating Scale (MADRS) score (Baseline 2, Week 8 Post-Psilocybin Dosing)
  • PROMIS Ability to Participate in Social Roles and Activities - Short Form 8a (Baseline 2, Week 8 Post-Dose)
  • Quality of Life Enjoyment and Satisfaction Questionnaire Short-Form (Q-LES-Q) score (Baseline 2, Week 8 Post-Dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-13
Completion: 2029-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 141 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Charles Raison
Collaborators: Usona Institute, Tiny Blue Dot Foundation, Steadman Philippon Research Institute, Emory University
Principal Investigators:
  • Charles Raison, MD (PRINCIPAL_INVESTIGATOR) - Vail Health Behavioral Health
Contact Information
Study Contact:
Program Manager
(970) 855-7374
bhic@vailhealth.org
Program Manager
(970) 855-7374
bhic@vailhealth.org
Vail Health Behavioral Health
Interventions
  • Drug: Psilocybin — The psilocybin used in this study is synthesized under Good Manufacturing Practice (GMP) guidelines and is provided in a capsule containing 25 mg of synthetic psilocybin.
  • Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) — Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear.
  • Device: Sham taVNS — Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear. In the sham condition, the device will simulate the sensations of active taVNS without delivering therapeutic stimulation.
Study Locations (1 sites)
Vail Health Behavioral Health, Edwards, Colorado 81632 United States
Eligibility Criteria
Inclusion Criteria: Current diagnosis of Major Depressive Disorder (MDD), with a depressive episode lasting ≥ 60 consecutive days at the time of screening, as confirmed by structured clinical interview Medically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject. Exclusion Criteria: History or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results (e.g., bipolar disorder, psychosis, seizure disorder, or cardiovascular disease). Known family history of a psychotic disorder (e.g., schizophrenia or schizoaffective disorder) in a first-degree relative (biological parent, full sibling, or child). Current active suicidal ideation with a specific plan within the prior 2 weeks, as assessed via clinical interview and validated instrument (e.g., C-SSRS). Suicide attempt within the prior 6 months, regardless of intent or lethality. Current diagnosis of a substance use disorder Abnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician). Unwilling or unable to discontinue prescription psychotropic medications (e.g., antidepressants, antipsychotics, anxiolytics, lithium, anticonvulsants, or mood stabilizers) for the duration of study participation, including any necessary washout period as determined by the investigator. Any condition, finding, or behavior (including suspected deception or noncompliance) that, in the opinion of the investigator, renders the participant unsuitable for the study or likely to interfere with the integrity of the data or safety of the subject.
Conditions Acute Stroke, Dysphagia
Phase NA
Enrollment 74
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to investigate the effects of chin tuck against resistance exercise on swallowing function, depression, and quality of life in acute stroke patients with dysphagia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: chin tuck against resistance exercise — Both groups of patients will receive traditional swallowing rehabilitation therapy; however, the experimental group will additionally perform CTAR exercises. The procedure is as follows:Ask the patient to sit, then, press the chin firmly against the inflatable rubber ball, for isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. And for isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions. Performing both isometric and isotonic exercises constitutes one set of exercises. For isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. For isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions.

Primary Outcomes

  • swallowing function (before intervention and up to 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-22
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 74 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Contact Information
Study Contact:
Fang-Ju Lin
+886-23123456
linfunzoe@ntuh.gov.tw
Fang-Ju Lin
Department of Nursing, National Taiwan University
Interventions
  • Behavioral: chin tuck against resistance exercise — Both groups of patients will receive traditional swallowing rehabilitation therapy; however, the experimental group will additionally perform CTAR exercises. The procedure is as follows:Ask the patient to sit, then, press the chin firmly against the inflatable rubber ball, for isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. And for isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions. Performing both isometric and isotonic exercises constitutes one set of exercises. For isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. For isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions.
Study Locations (1 sites)
Department of Nursing, National Taiwan University, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with hemorrhagic or ischemic stroke, including those with initial diagnoses or recurrent strokes. 2. Patients who did not pass the swallowing screening based on the standard swallowing scale. 3. Adults aged 18 years and older. 4. Vital signs are stable: systolic blood pressure (hemorrhagic \< 160 mmHg, ischemic \< 220 mmHg), heart rate 40-130 beats per minute, and oxygen saturation \> 92%. 5. The patient's consciousness is clear, able to express themselves, can communicate in Mandarin or Taiwanese, and can follow commands to perform actions. 6. The patient can be in a seated position. Exclusion Criteria: 1. Patients who have had a stroke for more than one month (inclusive). 2. Patients with a history of depression or related mental health disorders. 3. Patients with a history of neck pain, injury, or disease. 4. Patients who have previously undergone tracheostomy or have a tracheostomy tube in place.